Peritransplantation Use of Ruxolitinib in Myelofibrosis.

Biol Blood Marrow Transplant

Tisch Cancer Institute, Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.

Published: December 2020

Ruxolitinib is an oral JAK1/2 inhibitor that is approved for use in patients with intermediate and high-risk myelofibrosis (MF) based on its proven spleen and symptom burden reduction. Its impact on hematopoietic stem cell transplantation (HSCT) outcomes is largely unknown, however. A significant number of patients proceeding to HSCT have been treated with ruxolitinib, and the specifics of its peritransplantation use vary widely in the published literature. Here we review the currently published data and experience to guide management of patients with MF on ruxolitinib proceeding to HSCT.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2020.08.015DOI Listing

Publication Analysis

Top Keywords

proceeding hsct
8
peritransplantation ruxolitinib
4
ruxolitinib myelofibrosis
4
myelofibrosis ruxolitinib
4
ruxolitinib oral
4
oral jak1/2
4
jak1/2 inhibitor
4
inhibitor approved
4
approved patients
4
patients intermediate
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!